Endo Health Solutions this week announced that Watson Pharmaceuticals will be able to market its generic version of the pain medication Lidoderm beginning in 2013, according to an Investor's Business Daily report.
In a resolution to the longstanding conflict of when Lidoderm goes generic, Endo agreed to supply Watson with the drug in exchange for a 25 percent royalty until seven months pass or until another generic drug enters the market. Watson will begin marketing its generic version of Lidoderm on Sept. 15, 2013.
Endo's patent was originally set to expire in 2015, but Watson sued for an earlier date.
In a resolution to the longstanding conflict of when Lidoderm goes generic, Endo agreed to supply Watson with the drug in exchange for a 25 percent royalty until seven months pass or until another generic drug enters the market. Watson will begin marketing its generic version of Lidoderm on Sept. 15, 2013.
Endo's patent was originally set to expire in 2015, but Watson sued for an earlier date.
Related Articles on Pain Management:
10 Benchmarking Statistics About ASC Pain Management Revenue
IL Regulatory Board Expected to Consider Proposed Pain Management Surgery Center in Lisle
University of Maryland to Revamp Pain Education Curriculum